Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 11 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Renal Metabolic
Factor XI Inhibition and AF
Author(s): Bianca Rocca , Hugo ten Cate Added: 11 months ago

Anticoagulation

Electrophysiology & Arrhythmia
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 1 year ago

Anticoagulation
Symptomology, Outcomes and Risk Factors of Acute Coronary Syndrome Presentations without Cardiac Chest Pain: A Scoping Review
Author(s): Meriem Perona , Amanda Cooklin , Christopher Thorpe , et al Added: 1 year ago

MI/ACS
Separated Vasoreactivity Testing of ACH
Author(s): Shozo Sueda , Tomoki Sakaue Added: 1 year ago

Prevention & Chronic Conditions
AF Symposium 26: STYLE AF Update
Author(s): Roland R Tilz Added: 3 weeks ago
AF Symposium 2026 - Prof Roland Tilz (University Heart Center Lübeck, DE) presents updated findings from the STYLE AF study evaluating vascular closure strategies in patients undergoing atrial fibrillation ablation, with implications for procedural efficiency and same-day discharge protocols.Results demonstrated clear superiority of the vascular closure device across multiple clinically relevant… View more

Electrophysiology & Arrhythmia
The Coronary Microcirculation Re-explored
Author(s): Ahmed Elamin , Mustafa Abdimalik , Mohanad Abdelrahim , et al Added: 3 months ago

Prevention & Chronic Conditions
Lp(a) and Atherosclerosis
Author(s): Annalisa Filtz , Leandro Slipczuk , Martha Gulati Added: 1 week ago

Prevention & Chronic Conditions
ESC HF 25: The FIVE-STAR Trial
Author(s): Added: 9 months ago
ESC HF 25 - FIVE-STAR primary outcome is neutral, though finerenone was shown to significantly reduce UACR rates with a 29% greater reduction compared to placebo.We are joined by Dr Atsushi Tanaka (Saga University, Saga, JP) to discuss the findings from FIVE-STAR, a randomized trial investigating the effects of finerenone on vascular stiffness and cardiorenal biomarkers in patients with type 2… View more

Cardiovascular Renal Metabolic
CRT 24: The ABSORB Trial
Author(s): David Power Added: 1 year ago
CRT 24 - We are joined in this short virtual interview by investigator, Dr David Power (Mount Sinai Hospital, US) to discuss the latest findings from the ABSORB trial series, revealed in 2024 at the CRT conference.ABSORB III is a prospective, randomized, single-blind, multicenter trail aiming to support the pre-market approval of the Absorb bioresorbable vascular scaffold (Abbott) for the… View more

Intervention

Vascular Disease and Surgery